Skip to content
2000
Volume 22, Issue 8
  • ISSN: 1570-1794
  • E-ISSN: 1875-6271

Abstract

Introduction

The decreased anticancer activity of paclitaxel was associated with many factors. The inactivity of p53 was one of the important causes. Some chalcones and their derivatives were found to inhibit the MDM2-p53 interaction. Therefore, the conjugation of chalcones with paclitaxel might be an effective strategy for enhancing the antitumor activity of paclitaxel.

Methods

Here, three novel chalones, compounds , and were first designed and synthesized, followed by the conjugation of them with paclitaxel to prepare compounds , and . The anti-tumor activity of the aforementioned three novel paclitaxel-chalcone conjugates was evaluated by the MTT method, mitochondrial membrane potential analysis, apoptosis assay, and molecular docking.

Results

The MTT assay demonstrated that compound exhibited superior cytotoxicity compared to and toward breast cancer MCF-7 cells and MDA-MB-231 cells, with the differential activity correlating with electronic effects of their chalcone substituents: compound possessed two electron-withdrawing chlorine groups, compound lacked substitution, and compound featured an electron-donating morpholine. Compared to paclitaxel, compound 2a exhibited a 1.7-fold enhancement in cytotoxic activity against MCF-7 cells and a 2.5-fold increase in potency against MDA-MB-231 cells. Further investigation showed that compound could effectively decrease the mitochondrial membrane potential and induce cell apoptosis. Computational docking studies showed compound formed two hydrogen bonds and one π-H interaction with MDM2, with a docking score of -8.5317.

Discussion

Research findings demonstrate that the designed chalcone derivatives can effectively inhibit MDM2 activity, with the inhibitory potency closely associated with the substituents on the chalcone core. Notably, the introduction of chlorine substituents not only enhances the binding affinity to MDM2 but also improves the antitumor activity of its hybrid with paclitaxel. Molecular docking analysis reveals that the chlorine-substituted chalcone forms a π-H interaction with Gln72 of MDM2, a feature absent in the other two designed chalcone structures. Furthermore, the chlorine substituent may increase the lipophilicity of the hybrid, facilitating cellular uptake and thereby potentiating its anticancer efficacy.

Conclusion

These findings indicated that the conjugation of paclitaxel with chalones might be an effective strategy for strengthening the anticancer activity of paclitaxel.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cos/10.2174/0115701794395003250725111929
2025-08-12
2026-02-28

  • From This Site

    /content/journals/cos/10.2174/0115701794395003250725111929
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Abu SamaanT.M. SamecM. LiskovaA. KubatkaP. BüsselbergD. Paclitaxel’s mechanistic and clinical effects on breast cancer.Biomolecules201991278910.3390/biom9120789 31783552
     [Google Scholar]
  2. WeaverB.A. How Taxol/paclitaxel kills cancer cells.Mol. Biol. Cell201425182677268110.1091/mbc.e14‑04‑0916 25213191
     [Google Scholar]
  3. HayashiA. KamioK. MiyanagaA. YoshidaK. NoroR. MatsudaK. TozukaT. OmoriM. HiraoM. FukuizumiA. HisakaneK. TakeuchiS. MatsumotoM. KasaharaK. AmanoT. HondaK. SeikeM. Ivermectin enhances paclitaxel efficacy by overcoming resistance through modulation of ABCB1 in non-small cell lung cancer.Anticancer Res.202444125271528210.21873/anticanres.17355 39626921
     [Google Scholar]
  4. DengS. LiW. ChenQ. ShaoJ. ZhangJ. WangY. LiY. Developing a novel p-glycoprotein inhibitor and pairing it with oral paclitaxel liposomes for enhanced cancer therapy.Biomed. Pharmacother.2024180117577 Nov;10.1016/j.biopha.2024.11757739427547
     [Google Scholar]
  5. SaidA.M. MansourY.E. SolimanR.R. IslamR. FatahalaS.S. Design, synthesis, molecular modeling, in vitro and in vivo biological evaluation of potent anthranilamide derivatives as dual P-glycoprotein and CYP3A4 inhibitors.Eur. J. Med. Chem.202427311649210.1016/j.ejmech.2024.116492 38762918
     [Google Scholar]
  6. WangY. PeiW. YangY. XiaC. ZhangQ. GengZ. ShiX. WangF. Inhibition of XIST restrains paclitaxel resistance in breast cancer cells by targeting hsa-let-7d-5p/ATG16L1 through regulation of autophagy.Cell. Signal.202512711153410.1016/j.cellsig.2024.111534 39638138
     [Google Scholar]
  7. YangB. LiG. WangS. ZhengY. ZhangJ. PanB. WangN. WangZ. Tumor-associated macrophages/C-X-C motif chemokine ligand 1 promotes breast cancer autophagy-mediated chemoresistance via IGF1R/STAT3/HMGB1 signaling.Cell Death Dis.2024151074310.1038/s41419‑024‑07123‑5 39394189
     [Google Scholar]
  8. ZhengB. QianF. WangX. WangY. ZhouB. FangL. Neddylation activated TRIM25 desensitizes triple-negative breast cancer to paclitaxel via TFEB-mediated autophagy.J. Exp. Clin. Cancer Res.202443117710.1186/s13046‑024‑03085‑w 38926803
     [Google Scholar]
  9. XuH. DuZ. LiZ. LiuX. LiX. ZhangX. MaJ. MUC1-EGFR crosstalk with IL-6 by activating NF-κB and MAPK pathways to regulate the stemness and paclitaxel-resistance of lung adenocarcinoma.Ann. Med.2024561231367110.1080/07853890.2024.231367138325364
     [Google Scholar]
  10. TsurushimaK. TsubakiM. TakedaT. MatsudaT. KimuraA. TakefujiH. OkadaA. SakamotoC. IshizakaT. NishidaS. Dime-thyl fumarate induces apoptosis via inhibition of NF-κB and enhances the effect of paclitaxel and adriamycin in human TNBC cells.Int. J. Mol. Sci.20222315868110.3390/ijms23158681 35955813
     [Google Scholar]
  11. QiM. YiX. YueB. HuangM. ZhouS. XiongJ. S100A6 inhibits MDM2 to suppress breast cancer growth and enhance sensitivity to chemotherapy.Breast Cancer Res.20232515510.1186/s13058‑023‑01657‑w 37217945
     [Google Scholar]
  12. ShenH. DongW. GaoD. WangG. MaG. LiuQ. DuJ. MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel.Chin. Sci. Bull.20125791007101210.1007/s11434‑012‑4984‑7
     [Google Scholar]
  13. WeiC. DuJ. ShenY. WangZ. LinQ. ChenJ. ZhangF. LinW. WangZ. YangZ. MaW. Anticancer effect of involucrasin A on colorectal cancer cells by modulating the Akt/MDM2/p53 pathway.Oncol. Lett.202325621810.3892/ol.2023.13804 37153032
     [Google Scholar]
  14. HanN.R. KimH.Y. KangS. KimM.H. YoonK.W. MoonP.D. KimH.M. JeongH.J. Chrysophanol, an anthraquinone from AST2017-01, possesses the anti-proliferative effect through increasing p53 protein levels in human mast cells.Inflamm. Res.201968756957910.1007/s00011‑019‑01239‑7 31055607
     [Google Scholar]
  15. BhatiaN. KhatorR. KulkarniS. SinghY. KumarP. TharejaS. Recent advancements in the discovery of MDM2/MDM2-p53 inter-action inhibitors for the treatment of cancer.Curr. Med. Chem.202330323668370110.2174/0929867330666221114103924 37190755
     [Google Scholar]
  16. MuhseenZ.T. LiG. Promising terpenes as natural antagonists of cancer: An in-silico approach.Molecules201925115510.3390/molecules25010155 31906032
     [Google Scholar]
  17. MoreiraJ. AlmeidaJ. SaraivaL. CidadeH. PintoM. Chalcones as promising antitumor agents by targeting the p53 pathway: An overview and new insights in drug-likeness.Molecules20212612373710.3390/molecules26123737 34205272
     [Google Scholar]
  18. ChakrabartiK. PaulB. MajiM. RoyB.C. SheeS. KunduS. Bifunctional Ru(ii) complex catalysed carbon–carbon bond formation: An eco-friendly hydrogen borrowing strategy.Org. Biomol. Chem.20161446109881099710.1039/C6OB02010K 27827512
     [Google Scholar]
  19. BettoniL. SeckC. MbayeM.D. GaillardS. RenaudJ.L. Iron-catalyzed tandem three-component alkylation: Access to α-methylated substituted ketones.Org. Lett.20192193057306110.1021/acs.orglett.9b00630 31017447
     [Google Scholar]
  20. RammohanA. ReddyJ.S. SravyaG. RaoC.N. ZyryanovG.V. Chalcone synthesis, properties and medicinal applications: A review.Environ. Chem. Lett.202018243345810.1007/s10311‑019‑00959‑w
     [Google Scholar]
  21. ShalabyM.A. RizkS.A. FahimA.M. Synthesis, reactions and application of chalcones: A systematic review.Org. Biomol. Chem.202321265317534610.1039/D3OB00792H 37338020
     [Google Scholar]
  22. KarthikeyanC. Narayana MoorthyN.S.H. RamasamyS. VanamU. ManivannanE. KarunagaranD. TrivediP. Advances in chal-cones with anticancer activities.Recent Patents Anticancer Drug Discov.20141019711510.2174/1574892809666140819153902 25138130
     [Google Scholar]
  23. LeiteF.F. de SousaN.F. de OliveiraB.H.M. DuarteG.D. FerreiraM.D.L. ScottiM.T. FilhoJ.M.B. RodriguesL.C. de MouraR.O. Mendonça-JuniorF.J.B. ScottiL. Anticancer activity of chalcones and its derivatives: Review and in silico studies.Molecules20232810400910.3390/molecules28104009 37241750
     [Google Scholar]
  24. MaL. MaR. WangY. ZhuX. ZhangJ. ChanH.C. ChenX. ZhangW. ChiuS.K. ZhuG. Chalcoplatin, a dual-targeting and p53 activator-containing anticancer platinum(iv) prodrug with unique mode of action.Chem. Commun.201551296301630410.1039/C4CC10409A 25644651
     [Google Scholar]
  25. BhosleM.R. DeshmukhA.R. PalS. SrivastavaA.K. ManeR.A. Synthesis of new thiazolylmethoxyphenyl pyrimidines and antihy-perglycemic evaluation of the pyrimidines, analogues isoxazolines and pyrazolines.Bioorg. Med. Chem. Lett.201525112442244610.1016/j.bmcl.2015.03.068 25937008
     [Google Scholar]
  26. ZhangT. LiuY. XinH. TianJ. DengT. MengK. AnY. XueW. Synthesis and antifungal activity of chalcone derivatives contain-ing 1,3,4‐Thiadiazole.Chem. Biodivers.202421820240103110.1002/cbdv.202401031 38769733
     [Google Scholar]
  27. GreenwaldR.B. ZhaoH. ReddyP. Synthesis, isolation, and characterization of 2′-paclitaxel glycinate: An application of the Bsmoc protecting group.J. Org. Chem.200368124894489610.1021/jo034077s 12790596
     [Google Scholar]
  28. LuS. XiaR. WangJ. PeiQ. XieZ. JingX. Engineering paclitaxel prodrug nanoparticles via redox-activatable linkage and effective carriers for enhanced chemotherapy.ACS Appl. Mater. Interfaces20211339462914630210.1021/acsami.1c12353 34558902
     [Google Scholar]
  29. DaiY. ZhangY. YeT. ChenY. Synthesis and antitumor evaluation of biotin-SN38-valproic acid conjugates.Molecules2023289393610.3390/molecules28093936 37175346
     [Google Scholar]
  30. AlalawyA.I. Key genes and molecular mechanisms related to Paclitaxel Resistance.Cancer Cell. Int.202424124410.1186/s12935‑024‑03415‑0 39003454
     [Google Scholar]
  31. ŠkubníkJ. Svobodová PavlíčkováV. RumlT. RimpelováS. Autophagy in cancer resistance to paclitaxel: Development of combina-tion strategies.Biomed. Pharmacother.202316111445810.1016/j.biopha.2023.114458 36889112
     [Google Scholar]
  32. HashemiM. ZandiehM.A. TalebiY. RahmanianP. ShafieeS.S. NejadM.M. BabaeiR. SadiF.H. RajabiR. AbkenarZ.O. RezaeiS. RenJ. NabaviN. KhorramiR. RashidiM. HushmandiK. EntezariM. TaheriazamA. Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies.Biomed. Pharmacother.202316011439210.1016/j.biopha.2023.114392 36804123
     [Google Scholar]
  33. ZaibS. KhanI. HayyatA. AliN. GulA. NaveedM. Role of mitochondrial membrane potential and lactate dehydrogenase A in apoptosis.Anticancer. Agents Med. Chem.202222112048206210.2174/1871520621666211126090906 34825878
     [Google Scholar]
  34. LyJ.D. GrubbD.R. LawenA. The mitochondrial membrane potential (deltapsi(m)) in apoptosis; An update.Apoptosis20038211512810.1023/A:1022945107762 12766472
     [Google Scholar]
/content/journals/cos/10.2174/0115701794395003250725111929
Loading
The Conjugation of Paclitaxel with Chalcones for Enhancing Anti-tumor Activity
Curr. Org. Synth. 22, 921 (2025); https://doi.org/10.2174/0115701794395003250725111929
/content/journals/cos/10.2174/0115701794395003250725111929
/content/journals/cos/10.2174/0115701794395003250725111929
Loading

Data & Media loading...

Supplements

Supplementary material is available on the publisher's website along with the published article.

file format download Download

  • Article Type:     Research Article
Keyword(s): activity; anticancer; chalone; conjugate; Paclitaxel; synthesis

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test